EXTRAPYRAMIDAL EFFECTS INDUCED BY CHRONIC EXPOSURE TO METOCLOPRAMIDE AND HALOPERIDOL IN SWISS MICE
First-generation antipsychotics, such as haloperidol, have as their main mechanism of action the ability to block D2-like dopaminergic receptors type, in the central nervous system. These drugs are the main therapeutic strategy for a series of psychiatric and neurological disorders, including schizophrenia. Unfortunately, these medications have been extensively associated with debilitating motor side effects, extrapyramidal symptoms, which can be divided into hypokinetic (such as parkinsonism, or catalepsy), hyperkinetic (such as tardive dyskinesia, or vacuous chewing movement (VCMs)), or akinetic (inability to perform voluntary movements). Previous studies show that metoclopramide, an antiemetic drug that is also a D2R antagonist, may be able to induce extrapyramidal effects in humans and rodents, similarly to haloperidol. This work aimed to evaluate the behavioral effects of chronic exposure to metoclopramide (5 mg/kg or 8 mg/kg) and haloperidol (0.5 mg/kg) in Swiss mice and later to evaluate the modulation in the immunoreactivity of the ΔFosB protein, a transcription factor associated with long-term neuronal changes after chronic extracellular stimuli, already related to the induction of extrapyramidal effects by antipsychotics. In order to evaluate the participation of the nitrergic system, we performed the quantification of the nNOS protein. Histochemical evaluations were performed in the striatum, the main structure of the basal ganglia. We observed that metoclopramide, like haloperidol, induces catalepsy and VCMs and, in addition, modulates exploratory and motivational/emotional behaviors. At the biological level, there was an increase in ΔFosB immunoreactivity in the motor region of the striatum (dorsolateral), for haloperidol, and for metoclopramide at dose of 5 mg/kg. We also observed that chronic exposure to haloperidol or metoclopramide in Swiss mice does not alter the ΔFosB labeled cells in the other regions or nNOS in any of the striatal quadrants. These data suggest that greater attention should be paid to the indiscriminate use of metoclopramide, especially regarding the doses used and the exposure time.